Orally-Administered Silver Sulfadiazine: Chemotherapy and Toxicology in CF-1 Mice; <i>Plasmodium berghe</i><i>i</i> (Malaria) and <i>Pseudomonas aeruginosa</i>

Abstract

Silver sulfadiazine when administered orally and subcutaneously to CF-1 mice in doses not exceeding 1,050 mg/kg proved to have minimal toxicity. No pathology or abnormal reactions were seen in CF-1 mice after receiving 1,050 mg/kg orally and subcutaneously once a day for 30 days. Silver sulfadiazine in doses of 1,050 mg/kg, once a day for 5 days cured mice of Plasmodium berghei even after splenectomy. Parasitemia was reduced to zero in 1–3 days and antimalarial activity was not inhibited significantly with doses of 313 mg/kg/day of PABA, thereby indicating that silver sulfadiazine’s antimalarial mode of action is different from that of the sulfonamides. Doses of 1,050 mg/kg/day had significant activity against systemic infections of Pseudomonas aeruginosa.

Antimalarials: Screening of (Orally Administered) Silver Sulfonamides against <i>Plasmodium berghe</i><i>i</i>

“…aeruginosa but also against Plasmodium berghei in CF-1 mice. Unlike topical silver sulfadiazine, orally administered silver sulfadiazine is non-toxic in relatively large oral doses with no breakdown to free silver ions seen even after long use [8]. Unlike the topically ad ministered drug which is insoluble in water (0.1 /(M/100 ml) [9], orally administered silver sulfadiazine appears to be solubilized and absorbed from the gut.…”